Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910097 | 0.86 | GAA (0.51) | GAAHTTLMNAMAPTSMN1; SMN2 | |
| SCHEMBL3906738 | 0.84 | ITGB3 (0.44) | GAALMNAHDAC2AKR1C3AKR1C2 | |
| SCHEMBL407605 | 0.74 | KMO (0.67) | GAALMNAHDAC2MAPTSMN1; SMN2 | |
| SCHEMBL29446517 | 0.74 | KMO (0.67) | GAALMNAHDAC2MAPTSMN1; SMN2 | |
| SCHEMBL2586835 | 0.74 | KMO (0.59) | GAALMNAHDAC2DHFRMAPT | |
| SCHEMBL3910474 | 0.73 | GAA (0.60) | GAAHTTLMNAAKR1C3AKR1C2 | |
| SCHEMBL8015817 | 0.73 | CPN1 (0.53) | GAAHTTLMNASMN1; SMN2 | |
| SCHEMBL1520271 | 0.73 | GAA (0.54) | GAAHTTLMNASMN1; SMN2 | |
| SCHEMBL10389377 | 0.73 | MAPT (0.69) | GAALMNAHDAC2DHFRMAPT | |
| SCHEMBL10389918 | 0.72 | MAP4K4 (0.59) | GAALMNAHDAC2DHFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476759-B2 | e.g. 4-Amino-3-(4'-cyano-1,1'-biphenyl-4-yl)-4-oxobutanoic acid; antiinflammatory , anticarcinogenic, antiasthmatic agent; autoimmune disorder; osteoarthritis, rubella, Alzheimer's, Parkinson's diseases, epilepsy, osteoporosis | GLAXO GROUP LIMITED (GB) | 2009-01-13 | — | — | US | disclosed |
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1654218-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016868-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP9, MMP24 | GAA 1135/4885HTT 4566/4885LMNA 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.